Genomic Landscape of Young-Onset Bladder Cancer and Its Prognostic Implications on Adult Bladder Cancer
Autor: | Soo Jin Jung, Kyung Chul Moon, So Dug Lim, Song Yi Choi, Seo Hee Rha, Nam Hoon Cho, Jae Sung Lim, Ja Min Park, Jong Il Kim, Sun Young Yoon, Ok Jun Lee, Jeesoo Chae, Ho Won Kang, Ghee Young Kwon, Yeong Jin Choi, Hee Sang Hwang, S. Im, Sung Hyun Paick, Kun Suk Kim, Yong Mee Cho, Young Min Kim, Chang Ohk Sung, Jaeyong Choi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Cancer Research hras medicine.disease_cause lcsh:RC254-282 Article 03 medical and health sciences Exon 0302 clinical medicine medicine HRAS Exome sequencing next generation sequencing Mutation Bladder cancer business.industry Point mutation fgfr3 medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 030104 developmental biology Oncology young-onset bladder cancer 030220 oncology & carcinogenesis Cancer research ERCC2 KRAS prognosis business |
Zdroj: | Cancers, Vol 12, Iss 2, p 307 (2020) Cancers Volume 12 Issue 2 |
ISSN: | 2072-6694 |
Popis: | Due to the rare occurrence of young-onset bladder cancer (YBC), its genomic characteristics remain largely unknown. Twenty-nine biopsy-proven YBC cases were collected using a nation-wide search for bladder cancer diagnosed at 20 years or younger. Whole exome sequencing and RNA sequencing were carried out in 21 and 11 cases, respectively, and compared with those of adult bladder cancer (ABC) cases obtained from public databases. Almost all YBCs were low grade, non-invasive papillary tumors. YBC had a low mutation burden and less complex copy number alterations. All cases harbored putative driver mutations. Mutations were most commonly found in HRAS (10 cases), with a preference for exon 5. FGFR3 gene fusions were noted with various partner genes (7 cases). The alterations on HRAS and FGFR3 occurred in a mutually exclusive manner. Others included KRAS mutations (2 cases), chromosomes 4p and 10q arm-level deletions (1 case), and ERCC2 mutation (1 case). There were no point mutations in TP53 and FGFR3. The gene expression profiles of YBC were similar to those of the ABC group with good prognosis. None of the YBCs and ABCs with YBC-like mutations showed progression to muscle-invasive tumors. Our results suggest that bladder cancer with YBC-like mutations represents an indolent bladder tumor, regardless of age. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |